Cullinan Therapeutics (CGEM) EPS (Basic) (2021 - 2023)
Historic EPS (Basic) for Cullinan Therapeutics (CGEM) over the last 3 years, with Q4 2023 value amounting to -$28.97.
- Cullinan Therapeutics' EPS (Basic) fell 464918.03% to -$28.97 in Q4 2023 from the same period last year, while for Dec 2023 it was -$32.12, marking a year-over-year decrease of 139516.13%. This contributed to the annual value of -$27.78 for FY2024, which is 1351.18% up from last year.
- Cullinan Therapeutics' EPS (Basic) amounted to -$28.97 in Q4 2023, which was down 464918.03% from -$0.92 recorded in Q3 2023.
- Cullinan Therapeutics' EPS (Basic)'s 5-year high stood at $3.9 during Q2 2022, with a 5-year trough of -$28.97 in Q4 2023.
- Over the past 3 years, Cullinan Therapeutics' median EPS (Basic) value was -$0.57 (recorded in 2022), while the average stood at -$2.59.
- Its EPS (Basic) has fluctuated over the past 5 years, first surged by 118333.33% in 2022, then plummeted by 464918.03% in 2023.
- Over the past 3 years, Cullinan Therapeutics' EPS (Basic) (Quarter) stood at -$0.76 in 2021, then grew by 19.74% to -$0.61 in 2022, then crashed by 4649.18% to -$28.97 in 2023.
- Its EPS (Basic) was -$28.97 in Q4 2023, compared to -$0.92 in Q3 2023 and -$0.8 in Q2 2023.